

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

iSignthis Ltd

ABN

93 075 419 715

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

1. Ordinary fully paid shares

Appendix 3B
New issue announcement

- | | | |
|---|---|---|
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | <ol style="list-style-type: none">1. 43,860 Ordinary fully paid shares following the exercise of unlisted options (\$0.31, expiring 8/2/20)2. 110,000 Ordinary fully paid shares following the exercise of unlisted options (\$0.30, expiring 1/12/19)3. 41,667 Ordinary shares to be issued – (arising from the vesting and conversion of 41,667 Employee Performance Rights previously issued and having a conversion date of 1/9/19)4. 1,625,000 Ordinary shares to be issued – (arising from the vesting and conversion of 1,625,000 Director and Employee Performance Rights previously issued and converting following achievement of set criteria).5. 1,625,000 Ordinary shares to be issued – (arising from the vesting and conversion of 1,625,000 Director and Employee Performance Rights previously issued and converting following achievement of set criteria). |
|---|---|---|

+ See chapter 19 for defined terms.

3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

1. 43,860 Ordinary fully paid shares following the exercise of unlisted options (\$0.31, expiring 8/2/20)
2. 110,000 Ordinary fully paid shares following the exercise of unlisted options (\$0.30, expiring 1/12/19)
3. 41,667 Employee Performance Rights under the Company's Employee Incentive Plan. The performance conditions for these Employee Performance Rights have been satisfied. They now vest and are converted into an equivalent number of Ordinary Shares.
4. 1,625,000 Director and Employee Performance Rights under the Company's Employee Incentive Plan (includes Tranche A per Notice of Meeting issued on 11 April 2019). The performance conditions for these Employee Performance Rights have been satisfied. They now vest and are converted into an equivalent number of Ordinary Shares.
5. 1,625,000 Director and Employee Performance Rights under the Company's Employee Incentive Plan (includes Tranche B per Notice of Meeting issued on 11 April 2019). The performance conditions for these Employee Performance Rights have been satisfied. They now vest and are converted into an equivalent number of Ordinary Shares.

The grant of Employee Performance Rights under the Company's Employee Incentive Plan was approved by shareholders on the 28th November 2018 and a summary of the terms of the Employee Incentive Plan is set out in the Notice of Meeting released to the ASX on 26 October 2018.

Additional approval of Performance Rights issued to Directors was provided by shareholders at the AGM held on 17th May 2019. The Board has determined that the Performance Milestones have now been met (Tranche A being a 15-day VWAP of \$0.40 and Tranche B being a 15-day VWAP of \$0.50).

+ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

- | | |
|---|---|
| <p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | <ul style="list-style-type: none">• Yes. Ordinary shares issued following the exercise of unlisted options.• Yes. 41,667 fully paid Ordinary Shares (upon vesting and conversion of the Employee Performance Rights issued previously).• Yes. 3,250,000 fully paid Ordinary Shares (upon vesting and conversion of the Director and Employee Performance Rights issued previously). |
| <p>5 Issue price or consideration</p> | <ol style="list-style-type: none">1. Exercise price of \$0.31 per option for 43,860 options.2. Exercise price of \$0.30 per option for 110,000 options.3. Conversion of Performance Rights - nil |

+ See chapter 19 for defined terms.

6	<p>Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<ol style="list-style-type: none"> 1. Issuance of shares on the exercise of unlisted options 2. The Ordinary Shares (upon the vesting and conversion of Employee Performance Rights) were granted under the Company's Employee Incentive Plan, which was approved by shareholders on 28th November 2017. The purpose of the Employee Performance Rights is to link a component of the participant's remuneration to the performance of the Company and their individual performance. 3. The Ordinary Shares (upon the vesting and conversion of Employee Performance Rights) were granted under the Company's Employee Incentive Plan, which was approved by shareholders on 28th November 2017. The purpose of the Employee Performance Rights is to link a component of the participant's remuneration to the performance of the Company and their individual performance. <p style="text-align: center;">Performance Rights issued to Directors were approved by shareholders at the AGM held on 17th May 2019.</p>
6a	<p>Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the ⁺securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes</p>
6b	<p>The date the security holder resolution under rule 7.1A was passed</p>	<p>28 November 2018</p>
6c	<p>Number of ⁺securities issued without security holder approval under rule 7.1</p>	<p>Nil</p>
6d	<p>Number of ⁺securities issued with security holder approval under rule 7.1A</p>	<p>Nil</p>

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	The grant of Employee Performance Rights under the Company's Employee Incentive Plan was approved by shareholders on the 28 th November 2018 and a summary of the terms of the Employee incentive Plan is set out in the Notice of Meeting released to the ASX on 26 October 2018.				
6f	Number of +securities issued under an exception in rule 7.2	N/A				
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15-day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A				
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A				
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	158,072,854 under rule 7.1 109,043,569 under rule 7.1A				
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	2 nd September 2019				
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="708 1491 995 1525">Number</th> <th data-bbox="995 1491 1289 1525">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="708 1525 995 1742">1,092,968,191</td> <td data-bbox="995 1525 1289 1742">Ordinary fully paid shares</td> </tr> </tbody> </table>	Number	+Class	1,092,968,191	Ordinary fully paid shares
Number	+Class					
1,092,968,191	Ordinary fully paid shares					

+ See chapter 19 for defined terms.

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	300,000	Options (\$0.30, 1/12/19)
	1,164,913	Options (\$0.31, 8/02/20)
	3,000,000	Options (\$0.30, 10/07/20)
	10,000	Employee Incentive Performance Rights Converting to Ordinary Shares on 01/12/19
	62,500	Employee Incentive Performance Rights Converting to Ordinary Shares on 01/03/20
	1,995,000	Employee Incentive Performance Rights Converting to Ordinary Shares on 01/09/20
	180,000	Employee Incentive Performance Rights Converting to Ordinary Shares on 10/12/19
	50,000	Employee Incentive Performance Rights Converting to Ordinary Shares on 01/01/20
	74,000	Employee Incentive Performance Rights Converting to Ordinary Shares on 30/04/20
	69,000	Employee Incentive Performance Rights Converting to Ordinary Shares on 30/04/21
	101,625	Employee Incentive Performance Rights Converting to Ordinary Shares on 01/08/20
	101,625	Employee Incentive Performance Rights Converting to Ordinary Shares on 01/08/21

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change
---	-----------

Part 2 - Pro rata issue

11 Is security holder approval required?	N/A
--	-----

+ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	+Class of +securities to which the offer relates	N/A
15	+Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A
19	Closing date for receipt of acceptances or renunciations	N/A

+ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

+ See chapter 19 for defined terms.

Appendix 3B New issue announcement

- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 +Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of +securities
(tick one)
- (a) +Securities described in Part 1
- (b) All other +securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
- 37 A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought

39 +Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		

+ See chapter 19 for defined terms.

Appendix 3B New issue announcement

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Company secretary)

Date: 2nd September 2019

Print name: Todd Richards

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	1,004,832,159
<p>Add the following:</p> <ul style="list-style-type: none"> • Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>3/9/18 143,333 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>19/9/18 72,500 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>2/9/18 292,500 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>8/10/18 68,965,517 Fully paid ordinary shares as placement to institutional investors (approved 28/11/18)</p> <p>3/1/19 990,686 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>3/1/19 218,250 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>01/03/2019 1,250,000 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>05/03/2019 62,500 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>12/03/2019 85,000 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>12/04/2019 242,526 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>18/04/2019 77,193 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>26/04/2019 150,000 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>13/05/2019 2,748,396 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>20/05/2019 328,947 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>24/05/19 46,667 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>31/05/19 150,701 Fully Paid Ordinary Shares following exercise of unlisted options</p>

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

	<p>7/06/19 219,298 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>21/06/2019 1,096,491 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>2/07/2019 5,000,000 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>2/07/2019 17,500 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>02/09/19 43,860 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>02/09/19 110,000 Fully Paid Ordinary Shares following exercise of unlisted options</p> <p>2/09/2019 41,667 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>2/09/2019 1,625,000 Fully Paid Ordinary Shares following conversion of Performance Rights</p> <p>2/09/2019 1,625,000 Fully Paid Ordinary Shares following conversion of Performance Rights</p>
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil
“A”	1,090,435,691

+ See chapter 19 for defined terms.

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	163,565,354
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p><i>Insert</i> number of ⁺equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>8/10/18 1,408,609 Fully paid ordinary shares</p> <p>5/03/19 607,055 Fully paid ordinary shares</p> <p>13/03/19 3,000,000 Unlisted options</p> <p>8/08/19 476,836 Fully paid ordinary shares</p>
“C”	5,492,500
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	163,565,354
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	5,492,500
Total [“A” x 0.15] – “C”	158,072,854 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	1,090,435,691
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	109,043,569
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	Nil
“E”	0

+ See chapter 19 for defined terms.

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
<p>“A” x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	<p>109,043,569</p>
<p>Subtract “E”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	<p>0</p>
<p>Total [“A” x 0.10] – “E”</p>	<p style="text-align: center;">109,043,569</p> <p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

+ See chapter 19 for defined terms.